| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ACBAurora Cannabis Inc. | 239.88M | 4.24 | 148.77 | 27.01% | 7.68% | 4.54% | 0.17 | |
| IXHLIncannex Healthcare Limited | 132.26M | 0.38 | -0.28 | 378.7% | -1671.96% | -466.4% | 0.02 | |
| TLRYTilray Brands, Inc. | 1.13B | 9.71 | -0.29 | 4.84% | -252.55% | -136.55% | 0.22 | |
| IMCCIM Cannabis Corp. | 7.08M | 1.35 | -0.30 | 10.71% | -8.96% | -109.13% | 5.73 | |
| AKANAkanda Corp. | 190.81K | 1.31 | -0.33 | -61.27% | -12.14% | -8.5% | 0.08 | |
| INCRInterCure Ltd. | 52M | 0.95 | -0.67 | -32.82% | -28.38% | -17.05% | 0.53 | |
| FLGCFlora Growth Corp. | 6.84M | 6.54 | -5.03 | -21.78% | -32.14% | -24.58% | 1.09 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 106K | 8.98M | 33.4M | 76.07M | 59.51M |
| Revenue Growth % | - | - | 83.72% | 2.72% | 1.28% | -0.22% |
| Cost of Goods Sold | 25.86K | 35K | 6.55M | 20.15M | 58.33M | 47.01M |
| COGS % of Revenue | - | 0.33% | 0.73% | 0.6% | 0.77% | 0.79% |
| Gross Profit | -25.86K | 71K | 2.42M | 13.25M | 17.74M | 12.5M |
| Gross Margin % | - | 0.67% | 0.27% | 0.4% | 0.23% | 0.21% |
| Gross Profit Growth % | - | 3.75% | 33.15% | 4.46% | 0.34% | -0.3% |
| Operating Expenses | 2.79M | 14.36M | 21.43M | 60.47M | 68.09M | 28.14M |
| OpEx % of Revenue | - | 135.42% | 2.39% | 1.81% | 0.9% | 0.47% |
| Selling, General & Admin | 2.77M | 11.85M | 17.76M | 28.78M | 23.34M | 23.08M |
| SG&A % of Revenue | - | 111.76% | 1.98% | 0.86% | 0.31% | 0.39% |
| Research & Development | 21.04K | 78K | 132K | 388K | 62K | 418K |
| R&D % of Revenue | - | 0.74% | 0.01% | 0.01% | 0% | 0.01% |
| Other Operating Expenses | 0 | 2.43M | 3.54M | 31.31M | 44.7M | 4.65M |
| Operating Income | -2.82M | -14.28M | -19M | -47.22M | -50.35M | -15.64M |
| Operating Margin % | - | -134.75% | -2.12% | -1.41% | -0.66% | -0.26% |
| Operating Income Growth % | - | -4.07% | -0.33% | -1.48% | -0.07% | 0.69% |
| EBITDA | -2.79M | -14.17M | -18.5M | -44.59M | -48.02M | -14.88M |
| EBITDA Margin % | - | -133.69% | -2.06% | -1.34% | -0.63% | -0.25% |
| EBITDA Growth % | - | -4.07% | -0.31% | -1.41% | -0.08% | 0.69% |
| D&A (Non-Cash Add-back) | 25.86K | 113K | 501K | 2.63M | 2.33M | 768K |
| EBIT | -2.82M | -14.3M | -21.43M | -20.5M | -48.2M | -15.87M |
| Net Interest Income | 3.31K | -30K | -32K | 29K | -92K | -213K |
| Interest Income | 22.8K | 0 | 0 | 29K | 0 | 0 |
| Interest Expense | 19.48K | 30K | 32K | 0 | 92K | 213K |
| Other Income/Expense | -25.6K | -50K | -2.46M | -887K | 2.06M | -439K |
| Pretax Income | -2.84M | -14.33M | -21.46M | -48.11M | -48.3M | -16.08M |
| Pretax Margin % | - | -135.23% | -2.39% | -1.44% | -0.63% | -0.27% |
| Income Tax | 0 | 0 | -98K | -1.41M | -1.63M | -177K |
| Effective Tax Rate % | 1% | 0.99% | 0.99% | 1.09% | 1.18% | 0.99% |
| Net Income | -2.84M | -14.17M | -21.25M | -52.41M | -57.04M | -15.91M |
| Net Margin % | - | -133.68% | -2.37% | -1.57% | -0.75% | -0.27% |
| Net Income Growth % | - | -3.98% | -0.5% | -1.47% | -0.09% | 0.72% |
| Net Income (Continuing) | -2.84M | -14.33M | -21.36M | -46.7M | -46.67M | -15.91M |
| Discontinued Operations | 0 | 0 | 0 | -5.93M | -9.68M | 0 |
| Minority Interest | -11K | -113K | -225K | -411K | 0 | 0 |
| EPS (Diluted) | -0.65 | -8.13 | -6.52 | -13.73 | -7.33 | -1.30 |
| EPS Growth % | - | -11.51% | 0.2% | -1.11% | 0.47% | 0.82% |
| EPS (Basic) | -0.65 | -8.13 | -6.52 | -13.73 | -7.33 | -1.30 |
| Diluted Shares Outstanding | 4.39M | 1.75M | 3.28M | 3.83M | 7.36M | 12.27M |
| Basic Shares Outstanding | 4.39M | 1.75M | 3.28M | 3.83M | 7.36M | 12.27M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 461K | 17.63M | 47.94M | 31.16M | 21.36M | 19.76M |
| Cash & Short-Term Investments | 140K | 15.52M | 37.61M | 8.94M | 4.35M | 6.02M |
| Cash Only | 140K | 15.52M | 37.61M | 8.94M | 4.35M | 6.02M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 1.22M | 5.6M | 8.96M | 7.1M | 7.3M |
| Days Sales Outstanding | - | 4.21K | 227.5 | 97.9 | 34.08 | 44.79 |
| Inventory | 0 | 540K | 3.03M | 8.75M | 8.51M | 5.77M |
| Days Inventory Outstanding | - | 5.63K | 168.72 | 158.44 | 53.24 | 44.81 |
| Other Current Assets | 111K | 0 | 2K | 4.51M | 1.37M | 673K |
| Total Non-Current Assets | 712K | 1.82M | 37.54M | 49.83M | 2.26M | 6.46M |
| Property, Plant & Equipment | 435K | 729K | 4.98M | 3.34M | 1.24M | 1.61M |
| Fixed Asset Turnover | - | 0.15x | 1.80x | 10.01x | 61.55x | 36.98x |
| Goodwill | 0 | 431K | 20.05M | 23.37M | 0 | 2.01M |
| Intangible Assets | 277K | 658K | 9.74M | 17.74M | 946K | 2.75M |
| Long-Term Investments | 0 | 0 | 2.67M | 730K | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 97K | 4.66M | 80K | 103K |
| Total Assets | 1.17M | 19.45M | 85.48M | 80.99M | 23.63M | 26.23M |
| Asset Turnover | - | 0.01x | 0.11x | 0.41x | 3.22x | 2.27x |
| Asset Growth % | - | 15.58% | 3.39% | -0.05% | -0.71% | 0.11% |
| Total Current Liabilities | 2.23M | 2.74M | 6.12M | 17.45M | 16.28M | 18.83M |
| Accounts Payable | 328K | 1.81M | 2.42M | 7.83M | 5.11M | 5.46M |
| Days Payables Outstanding | 4.63K | 18.87K | 134.47 | 141.85 | 31.98 | 42.43 |
| Short-Term Debt | 1.03M | 251K | 18K | 1.09M | 1.93M | 2.08M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 2.03M | 5.65M | 6.59M | 7.77M |
| Current Ratio | 0.21x | 6.43x | 7.84x | 1.79x | 1.31x | 1.05x |
| Quick Ratio | 0.21x | 6.23x | 7.34x | 1.28x | 0.79x | 0.74x |
| Cash Conversion Cycle | - | -9.02K | 261.74 | 114.49 | 55.34 | 47.17 |
| Total Non-Current Liabilities | 246K | 459K | 2.42M | 7.13M | 942K | 2.88M |
| Long-Term Debt | 0 | 69K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 246K | 251K | 908K | 1.56M | 942K | 2.03M |
| Deferred Tax Liabilities | 0 | 139K | 1.51M | 1.71M | 0 | 856K |
| Other Non-Current Liabilities | 0 | 0 | 0 | 3.85M | 0 | 0 |
| Total Liabilities | 2.48M | 3.2M | 8.54M | 24.57M | 17.22M | 21.72M |
| Total Debt | 1.33M | 649K | 1.34M | 3.76M | 3.67M | 4.9M |
| Net Debt | 1.19M | -14.87M | -36.28M | -5.17M | -678K | -1.12M |
| Debt / Equity | - | 0.04x | 0.02x | 0.07x | 0.57x | 1.09x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -144.65x | -476.13x | -593.84x | - | -547.33x | -73.45x |
| Total Equity | -1.3M | 16.25M | 76.94M | 56.41M | 6.4M | 4.51M |
| Equity Growth % | - | 13.45% | 3.73% | -0.27% | -0.89% | -0.3% |
| Book Value per Share | -0.30 | 9.27 | 23.49 | 14.72 | 0.87 | 0.37 |
| Total Shareholders' Equity | -1.29M | 16.36M | 77.17M | 56.82M | 6.4M | 4.51M |
| Common Stock | 1.4M | 27.25M | 0 | 0 | 0 | 0 |
| Retained Earnings | -2.82M | -17.29M | -38.54M | -90.86M | -142.55M | -158.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 130K | 39K | -1.11M | -2.73M | -140K | -221K |
| Minority Interest | -11K | -113K | -225K | -411K | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -453.82K | -8.42M | -20.65M | -15.94M | -8.4M | -5.03M |
| Operating CF Margin % | - | -79.44% | -2.3% | -0.48% | -0.11% | -0.08% |
| Operating CF Growth % | - | -17.56% | -1.45% | 0.23% | 0.47% | 0.4% |
| Net Income | -2.84M | -14.33M | -21.36M | -52.63M | -47.36M | -15.91M |
| Depreciation & Amortization | 25.86K | 113K | 765K | 2.63M | 2.48M | 768K |
| Stock-Based Compensation | 1.81M | 4.9M | 1.34M | 3.4M | 1.59M | 2.78M |
| Deferred Taxes | -1.88M | 0 | -98K | -1.54M | -1.62M | -177K |
| Other Non-Cash Items | 1.6M | 1.77M | 3.74M | 28.38M | 37.16M | 4.36M |
| Working Capital Changes | 837.13K | -876K | -5.04M | 3.82M | -661K | 3.15M |
| Change in Receivables | -18.69K | -472K | -5.69M | 143K | 1.52M | -685K |
| Change in Inventory | 0 | -55K | -1.14M | 1.22M | 576K | 1.32M |
| Change in Payables | 0 | 0 | 3.05M | 1.09M | 0 | 0 |
| Cash from Investing | -431.23K | -2.16M | -14.55M | -15.8M | -234K | 203K |
| Capital Expenditures | -140.17K | -234K | -3.98M | -1.29M | -234K | -134K |
| CapEx % of Revenue | - | 2.21% | 0.44% | 0.04% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -390.02K | -1.2M | 29K | 0 | 0 | 273K |
| Cash from Financing | 1M | 25.82M | 58.11M | 4.41M | 3.15M | 6.49M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 1M | -3.11M | 15.79M | -333K | -396K | -1.27M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -593.99K | -8.65M | -24.63M | -17.23M | -8.56M | -5.17M |
| FCF Margin % | - | -81.65% | -2.74% | -0.52% | -0.11% | -0.09% |
| FCF Growth % | - | -13.57% | -1.85% | 0.3% | 0.5% | 0.4% |
| FCF per Share | -0.14 | -4.94 | -7.52 | -4.50 | -1.16 | -0.42 |
| FCF Conversion (FCF/Net Income) | 0.16x | 0.59x | 0.97x | 0.30x | 0.15x | 0.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -189.63% | -45.6% | -78.61% | -181.6% | -291.5% |
| Return on Invested Capital (ROIC) | - | -1700.48% | -67.8% | -77.07% | -132.59% | -257.35% |
| Gross Margin | - | 66.98% | 27% | 39.67% | 23.32% | 21% |
| Net Margin | - | -13367.92% | -236.63% | -156.93% | -74.98% | -26.73% |
| Debt / Equity | - | 0.04x | 0.02x | 0.07x | 0.57x | 1.09x |
| Interest Coverage | -144.65x | -476.13x | -593.84x | - | -547.33x | -73.45x |
| FCF Conversion | 0.16x | 0.59x | 0.97x | 0.30x | 0.15x | 0.32x |
| Revenue Growth | - | - | 8371.7% | 271.95% | 127.75% | -21.78% |
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| Pharmaceuticals and Nutraceuticals | 2.34M | - | - |
| Pharmaceuticals and Nutraceuticals Growth | - | - | - |
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| GERMANY | - | 38.26M | 35.87M |
| GERMANY Growth | - | - | -6.26% |
| UNITED STATES | - | 36.54M | 22.24M |
| UNITED STATES Growth | - | - | -39.13% |
| AUSTRALIA | - | - | 671K |
| AUSTRALIA Growth | - | - | - |
| United States | 1.68M | - | - |
| United States Growth | - | - | - |
| Canada | 380K | - | - |
| Canada Growth | - | - | - |
Flora Growth Corp. (FLGC) reported $49.7M in revenue for fiscal year 2024.
Flora Growth Corp. (FLGC) saw revenue decline by 21.8% over the past year.
Flora Growth Corp. (FLGC) reported a net loss of $16.0M for fiscal year 2024.
Flora Growth Corp. (FLGC) has a return on equity (ROE) of -291.5%. Negative ROE indicates the company is unprofitable.
Flora Growth Corp. (FLGC) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.